Publication:
Dynapenic abdominal obesity and metabolic health in non-geriatric patients with obesity

dc.contributor.coauthorAkbas, Feray
dc.contributor.coauthorAtmaca, Hanife Usta
dc.contributor.kuauthorDereli, Dilek Yazıcı
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.date.accessioned2024-12-29T09:38:55Z
dc.date.issued2023
dc.description.abstractBackground: Dynapenic abdominal obesity (DAO) is the combination of low muscle strength and high central adiposity, which can lead to functional and cardiometabolic impairments. Objective: The aim of this study was to examine the relationship between DAO and metabolic parameters in non-geriatric patients with obesity. Methods: All patients seen in the obesity outpatient clinic during a random month, along with 30 healthy individuals, were included in the study. Body mass index (BMI), waist circumference (WC), hip circumference (HC), serum fasting blood glucose, triglyceride, high-density lipoprotein, low-density lipoprotein (LDL), insulin, and glycated hemoglobin (HbA1c) levels were measured. Muscle function tests were conducted. Hypertension and diabetes mellitus diagnoses were recorded. DAO was determined using handgrip strength and WC. Metabolic syndrome was defined based on International Diabetes Federation (IDF) criteria. Data were analyzed using SPSS. Results: A total of 106 individuals participated in the study, including 76 individuals with obesity as the case group and 30 healthy individuals as the control group. In the case group, BMI, WC, HC, and chair stand test results were higher compared to the control group. There was no significant difference between the case and control groups in terms of gait speed or handgrip test results. In the case group, 30 people (39.5%) had dynapenic obesity (DO), and in the control group, 8 people (26.7%) had DO. There was no significant difference in DO rates between the case and control groups. In the case group, the HbA1c level was higher in DO (+) group than DO (-) group. In the control group, DO (+) group had higher LDL and HbA1c level than DO (-) group. No significant difference was observed in other search parameters between the DO (+) and DO (-) groups in both the case and control groups. Conclusion: DAO is common among people with obesity and contributes to a poor prognosis, increased morbidity, and mortality. Therefore, including its treatment in the management of obesity is crucial for individuals of all age ranges.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue1
dc.description.publisherscopeInternational
dc.description.volume22
dc.identifier.doi10.1089/met.2023.0153
dc.identifier.eissn1557-8518
dc.identifier.issn1540-4196
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85176407346
dc.identifier.urihttps://doi.org/10.1089/met.2023.0153
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22851
dc.identifier.wos1139374600001
dc.keywordsDynapenia
dc.keywordsDynapenic obesity
dc.keywordsObesity treatment
dc.languageen
dc.publisherMary Ann Liebert Inc.
dc.sourceMetabolic Syndrome and Related Disorders
dc.subjectMedicine
dc.subjectResearch
dc.subjectExperimental
dc.titleDynapenic abdominal obesity and metabolic health in non-geriatric patients with obesity
dc.typeJournal article
dspace.entity.typePublication
local.contributor.kuauthorDereli, Dilek Yazıcı

Files